

Ardex (Ardex Australia)

| Alder (Alder Australia) | Chemwalch Hazaru Alen Coue. Z |
|--|-------------------------------|
| Chemwatch: 5628-78 | Issue Date: 07/09/2023 |
| Version No: 2.1 | Print Date: 07/09/2023 |
| Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements | L.GHS.AUS.EN.E |

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

| Product name | ARDEX WPM155 Rapid Plus |
|-------------------------------|-------------------------|
| Chemical Name | Not Applicable |
| Synonyms | Not Available |
| Chemical formula | Not Applicable |
| Other means of identification | Not Available |

Relevant identified uses of the substance or mixture and uses advised against

| Relevant identified uses | Rapid drying under tile waterproofing product when used with Ardex STB tape. Use according to manufacturer's directions. |
|--------------------------|---|
|--------------------------|---|

Details of the manufacturer or supplier of the safety data sheet

| Registered company name | Ardex (Ardex Australia) |
|-------------------------|---|
| Address | 20 Powers Road Seven Hills NSW 2147 Australia |
| Telephone | 1800 224 070 |
| Fax | 1300 780 102 |
| Website | www.ardexaustralia.com |
| Email | sales@ardexaustralia.com |

Emergency telephone number

| · · · · · · · · · · · · · · · · · · · | |
|---------------------------------------|---------------------------------|
| Association / Organisation | Ardex (Ardex Australia) |
| Emergency telephone numbers | 1800 224 070 (Mon-Fri, 9am-5pm) |
| Other emergency telephone numbers | Not Available |

SECTION 2 Hazards identification

Classification of the substance or mixture

HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

Chemwatch Hazard Ratings

| | Min | Max | |
|--------------|-----|-----|-------------------------|
| Flammability | 0 | 1 | |
| Toxicity | 1 | | 0 = Minimum |
| Body Contact | 2 | 1 | 1 = Low |
| Reactivity | 0 | | 2 = Moderate |
| Chronic | 2 | 1 | 3 = High 4 = Extreme |

| Poisons Schedule | Not Applicable |
|--------------------|--|
| Classification [1] | Sensitisation (Skin) Category 1 |
| Legend: | 1. Classified by Chernwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI |

and Alart Caday 2

| Hazard pictogram(s) | |
|-------------------------------------|--|
| | |
| Signal word | Warning |
| Hazard statement(s) | |
| H317 | May cause an allergic skin reaction. |
| Precautionary statement(s) Pre | vention |
| P280 | Wear protective gloves and protective clothing. |
| P261 | Avoid breathing mist/vapours/spray. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| Precautionary statement(s) Response | |
| P302+P352 | IF ON SKIN: Wash with plenty of water. |

P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P362+P364 Take off contaminated clothing and wash it before reuse.

Precautionary statement(s) Storage

Not Applicable

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

| CAS No | %[weight] | Name |
|---------------|--|---|
| 7727-43-7 | 10-30 | barium sulfate |
| 9014-90-8 | <5 | nonylphenol sulfate, ethoxylated, sodium salt |
| 7664-41-7 | <1 | ammonia anhydrous liquefied |
| 55965-84-9 | <1 | isothiazolinones, mixed |
| 2682-20-4 | <1 | 2-methyl-4-isothiazolin-3-one |
| 2634-33-5 | <1 | 1,2-benzisothiazoline-3-one |
| Not Available | balance | Ingredients determined not to be hazardous |
| Legend: | 1. Classified by Chernwatch; 2. C Classification drawn from C&L * | Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. EU IOELVs available |

SECTION 4 First aid measures

Description of first aid measures

| Eye Contact | If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. |
|--------------|---|
| Skin Contact | If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation. |
| Inhalation | If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary. |
| Ingestion | If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice. |

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 Firefighting measures

Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances. In such an event consider:

- foam.
- dry chemical powder.
- carbon dioxide.

Special hazards arising from the substrate or mixture

| Fire Incompatibility | None known. |
|-------------------------|--|
| Advice for firefighters | |
| Fire Fighting | Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. |
| | The material is not readily combustible under normal conditions. However, it will break down under fire conditions and the organic component may burn. Not considered to be a significant fire risk. Heat may cause expansion or decomposition with violent rupture of containers. Decomposes on heating and may produce toxic fumes of carbon monoxide (CO). |

| | May emit acrid smoke. |
|-----------------------|--|
| Fire/Explosion Hazard | Decomposes on heating and produces toxic fumes of: carbon dioxide (CO2) nitrogen oxides (NOx) sulfur oxides (SOx) metal oxides other pyrolysis products typical of burning organic material. Decomposes at high temperatures to produce barium oxide. Barium oxide is strongly alkaline and, upon contact with water, is exothermic. When barium oxide reacts with oxygen to give a peroxide, there is a fire and explosion risk. May emit poisonous fumes. May emit corrosive fumes. |
| HAZCHEM | Not Applicable |

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

| Minor Spills | Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite. Wipe up. Place in a suitable, labelled container for waste disposal. |
|--------------|---|
| Major Spills | Absorb or contain isothiazolinone liquid spills with sand, earth, inert material or vermiculite. The absorbent (and surface soil to a depth sufficient to remove all of the biocide) should be shovelled into a drum and treated with an 11% solution of sodium metabisulfite (Na2S205) or sodium bisulfite (NaHSO3), or 12% sodium sulfite (Na2SO3) and 8% hydrochloric acid (HCI). Glutathione has also been used to inactivate the isothiazolinones. Use 20 volumes of decontaminating solution for each volume of biocide, and let containers stand for at least 30 minutes to deactivate microbicide before disposal. If contamination of drains or waterways occurs, advise emergency services. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. |

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling Safe handling Barbon Do NOT allow clothing wet with material to stay in contact with skin Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. DO NOT allow material to contact humans, exposed food or food utensils.

| | Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. Work clothes should be laundered separately. Launder contaminated clothing before re-use. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. |
|-------------------|--|
| Other information | Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained. Store in original containers. Keep containers securely sealed. Store in a cool, dry, well-ventilated area. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this SDS. |

Conditions for safe storage, including any incompatibilities

| | 5 , 1 |
|-------------------------|---|
| Suitable container | Polyethylene or polypropylene container. Packing as recommended by manufacturer. Check all containers are clearly labelled and free from leaks. |
| Storage incompatibility | None known |

SECTION 8 Exposure controls / personal protection

Not Available

Not Available

Not Available

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

| Source | Ingredient | Material name | TWA | STEL | Peak | Notes |
|------------------------------|--------------------------------|--------------------|----------------------|----------------------|------------------|--|
| Australia Exposure Standards | barium sulfate | Barium sulphate | 10 mg/m3 | Not Available | Not Available | (a) This value is for inhalable dust containing no asbestos and < 1% crystalline silica. |
| Australia Exposure Standards | ammonia anhydrous liquefied | Ammonia | 25 ppm / 17 mg/m3 | 24 mg/m3 / 35 ppm | Not Available | Not Available |

Emergency Limits

| Ingredient | TEEL-1 | TEEL-2 | | TEEL-3 |
|---|---------------|---------------|---------------|---------------|
| barium sulfate | 15 mg/m3 | 170 mg/m3 | | 990 mg/m3 |
| ammonia anhydrous liquefied | Not Available | Not Available | | Not Available |
| | | | | |
| Ingredient | Original IDLH | | Revised IDLH | |
| barium sulfate | Not Available | | Not Available | |
| nonylphenol sulfate, ethoxylated, sodium salt | Not Available | | Not Available | |
| ammonia anhydrous liquefied | 300 ppm | | Not Available | |

2-methyl-4-isothiazolin-3-one 1,2-benzisothiazoline-3-one

isothiazolinones, mixed

Occupational Exposure Banding

| Ingredient | Occupational Exposure Band Rating | Occupational Exposure Band Limit | |
|---|--|----------------------------------|--|
| nonylphenol sulfate, ethoxylated, sodium salt | E | ≤ 0.01 mg/m³ | |
| isothiazolinones, mixed | E | ≤ 0.1 ppm | |
| 2-methyl-4-isothiazolin-3-one | D | > 0.01 to ≤ 0.1 mg/m³ | |
| 1,2-benzisothiazoline-3-one | E | ≤ 0.01 mg/m³ | |
| Notes: | Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a | | |

adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.

Not Available

Not Available

Not Available

MATERIAL DATA

Exposure controls

| - | |
|-------------------------------------|---|
| Appropriate engineering controls | Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the risk. Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure. |
| | General exhaust is adequate under normal operating conditions. Local exhaust ventilation may be required in special circumstances. If risk of overexposure exists, wear approved respirator. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection. Provide adequate ventilation in warehouses and enclosed storage areas. Air contaminants generated in the |

| | workplace possess varying "escape" velocities which, in turn, remove the contaminant. | determine the "capture velocities" of fresh circulating air re- | quired to effectively | |
|---|--|--|--|--|
| | Type of Contaminant: | Air Speed: | | |
| | solvent, vapours, degreasing etc., evaporating from tank (ir | 0.25-0.5 m/s (50-100 f/min) | | |
| | aerosols, fumes from pouring operations, intermittent conta drift, plating acid fumes, pickling (released at low velocity in | 0.5-1 m/s (100-200 f/min.) | | |
| | direct spray, spray painting in shallow booths, drum filling, o generation into zone of rapid air motion) | 1-2.5 m/s (200-500 f/min.) | | |
| | grinding, abrasive blasting, tumbling, high speed wheel ger very high rapid air motion) | erated dusts (released at high initial velocity into zone of | 2.5-10 m/s (500-2000 f/min.) | |
| | Within each range the appropriate value depends on: | | | |
| | Lower end of the range | Upper end of the range | | |
| | 1: Room air currents minimal or favourable to capture | 1: Disturbing room air currents | | |
| | 2: Contaminants of low toxicity or of nuisance value only. | 2: Contaminants of high toxicity | | |
| | 3: Intermittent, low production. | 3: High production, heavy use | | |
| | 4: Large hood or large air mass in motion | 4: Small hood-local control only | | |
| | Simple theory shows that air velocity falls rapidly with distance with the square of distance from the extraction point (in simpl accordingly, after reference to distance from the contamination 1-2 m/s (200-400 f/min) for extraction of solvents generated in producing performance deficits within the extraction apparatu more when extraction systems are installed or used. | e away from the opening of a simple extraction pipe. Veloci e cases). Therefore the air speed at the extraction point sho g source. The air velocity at the extraction fan, for example a tank 2 meters distant from the extraction point. Other me s, make it essential that theoretical air velocities are multipli | ty generally decreases vuld be adjusted, should be a minimum of echanical considerations, ed by factors of 10 or | |
| Individual protection measures, such as personal protective equipment | | | | |
| Eye and face protection | Safety glasses with side shields. Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent] Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59]. | | | |
| Skin protection | See Hand protection below | | | |
| Hands/feet protection | Wear chemical protective gloves, e.g. PVC. Wear safety footwear or safety gumboots, e.g. Rubber NOTE: The material may produce skin sensitisation in predispose equipment, to avoid all possible skin contact. Contaminated leather items, such as shoes, belts and way The selection of suitable gloves does not only depend on the manufacturer. Where the chemical is a preparation of several and has therefore to be checked prior to the application. The exact break through time for substances has to be obtain making a final choice. Personal hygiene is a key element of effective hand care. Glo washed and dried thoroughly. Application of a non-perfumed Suitability and durability of glove type is dependent on usage if requency and duration of contact, chemical resistance of glove material, glove thickness and dexterity Select gloves tested to a relevant standard (e.g. Europe EN 3: When prolonged or frequently repeated contact may occur, minutes according to EN 374, AS/NZS 2161.10.1 or national When only brief contact is expected, a glove with a protectiod 374, AS/NZS 2161.10.1 or national When only brief contact is expected, a glove with a protectiod 374, AS/NZS 2161.10.1 or national equivalent) is recomment a Contaminated gloves should be replaced. As defined in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any application, gloves are reference in ASTM F-739-96 in any appli | ed individuals. Care must be taken, when removing gloves ttch-bands should be removed and destroyed. material, but also on further marks of quality which vary fro substances, the resistance of the glove material can not be red from the manufacturer of the protective gloves and has wes must only be worn on clean hands. After using gloves, moisturiser is recommended. Important factors in the selection of gloves include: 174, US F739, AS/NZS 2161.1 or national equivalent). a glove with a protection class of 5 or higher (breakthrough equivalent) is recommended. In class of 3 or higher (breakthrough time greater than 60 m led. nd this should be taken into account when considering glove ated as: ater than 0.35 mm, are recommended. Iy a good predictor of glove resistance to a specific chemic: ition of the glove material. Therefore, glove selection should akthrough times. facturer, the glove type and the glove model. Therefore, the of the most appropriate glove for the task. arying thickness may be required for specific tasks. For exa here a high degree of manual dexterity is needed. However | and other protective m manufacturer to e calculated in advance to be observed when hands should be time greater than 240 inutes according to EN es for long-term use. al, as the permeation d also be based on manufacturers technical mple: , these gloves are only | |

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed

| | moisturiser is recommended. ▶ Butyl rubber gloves • Nitrile rubber gloves (Note: Nitric acid penetrates nitrile gloves in a few minutes.) |
|------------------|---|
| Body protection | See Other protection below |
| Other protection | Overalls. P.V.C apron. Barrier cream. Skin cleansing cream. Evo wach unit. |

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

ARDEX WPM155 Rapid Plus

| Material | CPI |
|------------------|-----|
| BUTYL | С |
| BUTYL/NEOPRENE | С |
| CPE | С |
| NATURAL RUBBER | С |
| NATURAL+NEOPRENE | С |
| NEOPRENE | С |
| NEOPRENE/NATURAL | С |
| NITRILE | С |
| PE | С |
| PE/EVAL/PE | С |
| PVA | С |
| PVC | С |
| SARANEX-23 | С |
| TEFLON | С |
| VITON | С |
| VITON/NEOPRENE | С |

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type BKAX-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

| Required Minimum Protection Factor | Half-Face Respirator | Full-Face Respirator | Powered Air Respirator |
|---------------------------------------|-------------------------|--------------------------|-------------------------------|
| up to 10 x ES | BKAX-AUS P2 | - | BKAX-PAPR-AUS / Class 1 P2 |
| up to 50 x ES | - | BKAX-AUS / Class 1 P2 | - |
| up to 100 x ES | - | BKAX-2 P2 | BKAX-PAPR-2 P2 ^ |

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.

 The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).

 Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.

 Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.

 Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU)

Use approved positive flow mask if significant quantities of dust becomes airborne.
 Try to avoid creating dust conditions.

Class P2 particulate filters are used for protection against mechanically and thermally generated particulates or both.

P2 is a respiratory filter rating under various international standards, Filters at least 94% of airborne particles

Suitable for:

 \cdot Relatively small particles generated by mechanical processes eg. grinding, cutting, sanding, drilling, sawing.

 Sub-micron thermally generated particles e.g. welding fumes, fertilizer and bushfire smoke.

 Biologically active airborne particles under specified infection control applications e.g. viruses, bacteria, COVID-19, SARS

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

| Appearance | Bluish grey liquid; partly mixes with water. | | | |
|----------------|--|------------------------------|---------------|--|
| Physical state | Liquid | Relative density (Water = 1) | Not Available | |

| Odour | Not Available | Partition coefficient n-octanol / water | Not Available |
|---|-----------------|--|----------------|
| Odour threshold | Not Available | Auto-ignition temperature (°C) | Not Applicable |
| pH (as supplied) | Not Available | Decomposition temperature (°C) | Not Available |
| Melting point / freezing point (°C) | Not Applicable | Viscosity (cSt) | Not Available |
| Initial boiling point and boiling range (°C) | Not Available | Molecular weight (g/mol) | Not Applicable |
| Flash point (°C) | Not Applicable | Taste | Not Available |
| Evaporation rate | Not Available | Explosive properties | Not Available |
| Flammability | Not Applicable | Oxidising properties | Not Available |
| Upper Explosive Limit (%) | Not Applicable | Surface Tension (dyn/cm or mN/m) | Not Available |
| Lower Explosive Limit (%) | Not Applicable | Volatile Component (%vol) | Not Available |
| Vapour pressure (kPa) | Not Available | Gas group | Not Available |
| Solubility in water | Partly miscible | pH as a solution (1%) | Not Available |
| Vapour density (Air = 1) | Not Available | VOC g/L | Not Available |

SECTION 10 Stability and reactivity

| Reactivity | See section 7 |
|-------------------------------------|--|
| Chemical stability | Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur. |
| Possibility of hazardous reactions | See section 7 |
| Conditions to avoid | See section 7 |
| Incompatible materials | See section 7 |
| Hazardous decomposition products | See section 5 |

SECTION 11 Toxicological information

Information on toxicological effects

| Inhaled | Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Barium fumes are respiratory irritants. Over-exposure to barium dusts and fume may result in rhinitis, frontal headache, wheezing, laryngeal spasm, salivation and anorexia. Long term effects include nervous disorders and adverse effects on the heart, circulatory system and musculature. Heavy exposures may result in a benign pneumoconiosis. |
|--------------|---|
| Ingestion | Accidental ingestion of the material may be damaging to the health of the individual. |
| Skin Contact | The material may accentuate any pre-existing dermatitis condition Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. Limited evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. |
| Eye | Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur. |
| Chronic | Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals. Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive. Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers Wherever it is reasonably practicable, exposure to substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive. Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or |

biochemical systems In a teratogenic study in rats concentrations of up to 40 mg/kg 1,2-benzisothiazoline-3-one (BIT) were neither embryotoxic nor teratogenic. The material is not mutagenic. In a 2-year carcinogenicity study with rats, BIT did not produce excess tumours. The results derived from this test are questionable because no dose series was administered and because there were too few animals A 90-day study with beagle dogs receiving oral doses showed reduced food consumption and body weight gain as well as mild anaemia, increases in the weights of liver and in male animals, brain and spleen weights. The no-observed-effect-level (NOEL) was given as 165 mg/kg (ie 0.5 BIT in the diet). A 90-day study with rats receiving dietary BIT showed reduced liver and pituitary weights in males. The NOEL was less than 0.1 %. The isothiazolinones are known contact sensitisers. Data are presented which demonstrate that, in comparison with the chlorinated and dichlorinated compounds which share immunological cross-reactivity, the non-chlorinated isothiazolinones have a lower potential for sensitization and no documented immunological cross-reaction with the chlorinated isothiazolinones. The risk of sensitization depends on how contact with the product occurs. The risk is greater when the skin barrier has been damaged and smaller when the skin is healthy. Dermatological studies have demonstrated that mixed isothiazolinone concentrations below 20 ppm may cause sensitisation and that allergic reactions can be provoked in sensitized persons even with concentrations in the range of 7-15 ppm active isothiazolinones. The isothiazolinones are a group of heterocyclic sulfur-containing compounds. In general all are electrophilic molecules containing an activated N-S bond that enables them with nucleophilic cell entities, thus exerting biocidal activity. A vinyl activated chlorine atom makes allows to molecule to exert greater antimicrobial efficiency but at the same time produces a greater potential for sensitisation. Several conclusions relating to the sensitising characteristics of the isothiazolinones may therefore be drawn*: The strongest sensitisers are the chlorinated isothiazolinones. There are known immunological cross-reactions between at least 2 different chlorinated isothiazolinones. There appears to be no immunological cross reaction between non-chlorinated isothiazolinones and chlorinated isothiazolinones. Although classified as sensitisers, the nonchlorinated isothiazolinones are considerably less potent sensitisers than are the chlorinated isothiazolinones. By avoiding the use of chlorinated isothiazolinones, the potential to induce sensitisation is greatly reduced. Despite a significant percentage of the population having been previously sensitised to chlorinated and non-chlorinated species, it is likely that careful and judicious use of non-chlorinated isothiazolinones will result in reduced risk of allergic reactions in those persons Although presently available data promise that several non-chlorinated isothiazolinones will offer effective antimicrobial protection in industrial and personal care products, it is only with the passage of time that proof of their safety in use or otherwise will become available. * B.R. Alexander: Contact Dermatitis 2002, 46, pp 191-196 Although there have been conflicting reports in the literature, it has been reported by several investigators that isothiazolinones are mutagenic in Salmonella typhimurium strains (Ames test). Negative results were obtained in studies of the DNA-damaging potential of mixed isothiazolinones (Kathon) in mammalian cells in vitro and of cytogenetic effects and DNA-binding in vivo. The addition of rat liver S-9 (metabolic activation) reduced toxicity but did not eliminate mutagenicity. These compounds bind to the proteins in the S-9. At higher concentrations of Kathon the increase in mutagenicity may be due to an excess of unbound active compounds. A study of cutaneous application of Kathon CG in 30 months, three times per week at a concentration of 400 ppm (0.04%) a.i. had no local or systemic tumourigenic effect in male mice. No dermal or systemic carcinogenic potential was observed. Reproduction and teratogenicity studies with rats, given isothiazolinone doses of 1.4-14 mg/kg/day orally from day 6 to day 15 of gestation, showed no treatment related effects in either the dams or in the foetuses Workers exposed to barium compounds have been reported to show an increased incidence of hypertension, irritation of the respiratory system, and damage to the spleen, liver and bone marrow. Long term exposure to some barium compounds (especially inorganic species) may produce a condition known as baritosis, a form of benign pneumoconiosis. X-ray may show this when no other abnormal signs are present. Symptoms of pneumoconiosis may include a progressive dry cough, shortness of breath on exertion, increased chest expansion, weakness and weight loss. As the disease progresses the cough produces a stringy mucous, vital capacity decreases further and shortness of breath becomes more severe. Pneumoconiosis is the accumulation of dusts in the lungs and the tissue reaction in its presence. Barium sulfate produces noncollagenous pneumoconiosis identified by minimal stromal reaction, consisting mainly of reticulin fibres, an intact alveolar architecture and is potentially reversible. Miners of ores containing barium sulfate do not show symptoms, abnormal physical signs, an incapacity to work, diminished lung function, an increased likelihood of developing pulmonary or other bronchial infections or other thoracic disease despite the fact that particulate matter may have been retained in the lungs for many years. No changes in mortality were observed in rats chronically exposed to doses as high as 60 mg barium/kg/day as barium chloride in the drinking water. An increase in mortality, attributable to nephropathy, was observed in mice chronically exposed to 160 mg barium/kg/day as barium chloride in drinking water; the number of deaths was similar to controls in mice exposed to 75 mg barium/kg/day. In male mice exposed to 0.95 mg barium/kg/day as barium acetate in drinking water, a significant decrease in longevity (defined as average lifespan of the last five surviving animals) was observed; however, no significant differences in mean lifespan were observed. Similarly, lifespan was not significantly altered in female mice exposed to 0.95 mg barium/kg/day or male or female rats exposed to 0.7 mg barium/kg/day as barium acetate in drinking water. The potential for barium to induce reproductive and developmental effects has not been well investigated. Decreases in the number of sperm and sperm quality and a shortened estrous cycle and morphological alterations in the ovaries were observed in rats exposed to 2.2 mg barium/m3 and higher in air for an intermediate duration. Interpretation of these data is limited by the poor reporting of the study design and results, in particular, whether the incidence was significantly different from controls. In general, oral exposure studies have not found morphological alterations in reproductive tissues of rats or mice exposed to 180 or 450 mg barium/kg/day, respectively, as barium chloride in drinking water for an intermediate duration. Additionally, no significant alterations in reproductive performance was observed in rats or mice exposed to 200 mg barium/kg/day as barium chloride in drinking water. Decreased pup birth weight and a nonsignificant decrease in litter size have been observed in the offspring of rats exposed to 180/200 mg barium/kg/day as barium chloride in drinking water prior to mating. Several studies have examined the carcinogenic potential of barium following oral exposure and did not find significant increases in the tumour incidence TOXICITY IRRITATION ARDEX WPM155 Rapid Plus Not Available Not Available TOXICITY IRRITATION

| nonylphenol sulfate, |
|----------------------|

barium sulfate

dermal (rat) LD50: >2000 mg/kg^[1]

Oral (Mouse) LD50; >3000 mg/kg^[2]

Oral (Rat) LD50: >5000 mg/kg^[2]

Oral (Rat) LD50: 350 mg/kg^[2]

dermal (rat) LD50: >1008 mg/kg[1]

Inhalation(Rabbit) LC50; 4.55 ppm4h^[2]

TOXICITY

TOXICITY

TOXICITY

ethoxylated, sodium salt

ammonia anhydrous liquefied

isothiazolinones, mixed

Eye: adverse effect observed (irreversible damage)^[1]

Not Available

IRRITATION

Not Available

IRRITATION

Not Available

IRRITATION

Continued...

| | Inhalation(Rat) LC50: 0.171 mg/l4h ^[1] | Skin: adverse effect observed (corrosive) ^[1] | |
|-------------------------------|--|--|--|
| | Oral (Rat) LD50: 53 mg/kg ^[2] | Skin: adverse effect observed (irritating) ^[1] | |
| | ΤΟΧΙΟΙΤΥ | IRRITATION | |
| | dermal (rat) LD50: 242 mg/kg ^[1] | Eye: adverse effect observed (irreversible damage) ^[1] | |
| 2-methyl-4-isothiazolin-3-one | Inhalation(Rat) LC50: 0.1 mg/l4h ^[1] | Skin: adverse effect observed (corrosive) ^[1] | |
| | Oral (Rat) LD50: 120 mg/kg ^[1] | | |
| | ΤΟΧΙΟΙΤΥ | IRRITATION | |
| 1,2-benzisothiazoline-3-one | dermal (rat) LD50: >2000 mg/kg ^[1] | Eye: adverse effect observed (irreversible damage) ^[1] | |
| | Oral (Rat) LD50: 454 mg/kg ^[1] | Skin: no adverse effect observed (not irritating) ^[1] | |
| Legend: | 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances | | |
| | For nonylphenol and its compounds: Alkylphenols like nonylphenol and bisphenol A have es and other endocrine disruptors are compounds that ha binding to estrogen receptors and acting competitively protein-coupled estrogen receptor),. Nonylphenol has l endogeous hormone for binding with the estrogen rece Effects in pregnant women. Subcutaneous injections of nonylphenol in late pregna which suggest it can be transferred through the placen placenta than the endogenous estrogen 17beta-estrad is generative in gladenthy is placenth endo | strogenic effects in the body. They are known as xenoestrogens. Estrogenic substances ve hormone-like effects in both wildlife and humans. Xenoestrogens usually function by against natural estrogens. Nonylphenol has been found to act as an agonist of GPER (G been shown to mimic the natural hormone 17beta-estradiol, and it competes with the eptors ERalpha and ERbeta. ncy causes the expression of certain placental and uterine proteins, namely CaBP-9k, ta to the fetus. It has also been shown to have a higher potency on the first trimester iol. In addition, early prenatal exposure to low doses of nonylphenol cause an increase | |

found in the environment Nonylphenol has also been shown to affect cytokine signaling molecule secretions in the human placenta. In vitro cell cultures of human placenta during the first trimester were treated with nonylphenol, which increase the secretion of cytokines including interferon gamma, interleukin 4, and interleukin 10, and reduced the secretion of tumor necrosis factor alpha. This unbalanced cytokine profile at this part of

pregnancy has been documented to result in implantation failure, pregnancy loss, and other complications. Effects on metabolism

Nonylphenol has been shown to act as an obesity enhancing chemical or obesogen, though it has paradoxically been shown to have anti-obesity properties. Growing embryos and newborns are particularly vulnerable when exposed to nonylphenol because low-doses can disrupt sensitive processes that occur during these important developmental periods. Prenatal and perinatal exposure to nonylphenol has been linked with developmental abnormalities in adipose tissue and therefore in metabolic hormone synthesis and release. Specifically, by acting as an estrogen mimic, nonylphenol has generally been shown to interfere with hypothalamic appetite control. The hypothalamus responds to the hormone leptin, which signals the feeling of fullness after eating, and nonylphenol has been shown to both increase and decrease eating behavior by interfering with leptin signaling in the midbrain. Nonylphenol has been shown mimic the action of leptin on neuropeptide Y and anorectic POMC neurons, which has an anti-obesity effect by decreasing eating behavior. This was seen when estrogen or estrogen mimics were injected into the ventromedial hypothalamus. On the other hand, nonylphenol has been shown to increase food intake and have obesity enhancing properties by lowering the expression of these anorexigenic neurons in the brain. Additionally, nonviblenol affects the expression of ghrelin: an enzyme produced by the stomach that stimulates appetite. Ghrelin expression is positively regulated by estrogen signaling in the stomach, and it is also important in guiding the differentiation of stem cells into adipocytes (fat cells). Thus, acting as an estrogen mimic, prenatal and perinatal exposure to nonylphenol has been shown to increase appetite and encourage the body to store fat later in life. Finally, long-term exposure to nonylphenol has been shown to affect insulin signaling in the liver of adult male rats. Cancer

NONYLPHENOL SULFATE ETHOXYLATED, SODIUM SALT

to its agonistic activity on ERalpha (estrogen receptor alpha) in estrogen-dependent and estrogen-independent breast cancer cells. Some argue that nonylphenol's suggested estrogenic effect coupled with its widespread human exposure could potentially influence hormonedependent breast cancer disease Polyethers, for example, ethoxylated surfactants and polyethylene glycols, are highly susceptible towards air oxidation as the ether oxygens will stabilize intermediary radicals involved. Investigations of a chemically well-defined alcohol (pentaethylene glycol mono-n-dodecyl ether) ethoxylate, showed that polyethers form complex mixtures of oxidation products when exposed to air. Sensitization studies in guinea pigs revealed that the pure nonoxidized surfactant itself is nonsensitizing but that many of the investigated

oxidation products are sensitizers. Two hydroperoxides were identified in the oxidation mixture, but only one (16-hydroperoxy-3,6,9,12,15pentaoxaheptacosan-1-ol) was stable enough to be isolated. It was found to be a strong sensitizer in LLNA (local lymph node assay for detection of sensitization capacity). The formation of other hydroperoxides was indicated by the detection of their corresponding aldehydes in the oxidation mixture .

Nonviphenol exposure has also been associated with breast cancer. It has been shown to promote the proliferation of breast cancer cells, due

On the basis of the lower irritancy, nonionic surfactants are often preferred to ionic surfactants in topical products. However, their susceptibility towards autoxidation also increases the irritation. Because of their irritating effect, it is difficult

to diagnose ACD to these compounds by patch testing.

Allergic Contact Dermatitis—Formation, Structural Requirements, and Reactivity of Skin Sensitizers. Ann-Therese Karlberg et al; Chem. Res. Toxicol.2008,21,53-69

Polyethylene glycols (PEGs) have a wide variety of PEG-derived mixtures due to their readily linkable terminal primary hydroxyl groups in combination with many possible compounds and complexes such as ethers, fatty acids, castor oils, amines, propylene glycols, among other derivatives. PEGs and their derivatives are broadly utilized in cosmetic products as surfactants, emulsifiers, cleansing agents, humectants, and skin conditioners.

PEGs and PEG derivatives were generally regulated as safe for use in cosmetics, with the conditions that impurities and by-products, such as ethylene oxides and 1,4-dioxane, which are known carcinogenic materials, should be removed before they are mixed in cosmetic formulations. Most PEGs are commonly available commercially as mixtures of different oligomer sizes in broadly- or narrowly-defined molecular weight (MW) ranges. For instance, PEG-10,000 typically designates a mixture of PEG molecules (n = 195 to 265) having an average MW of 10,000. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), with the three names being chemical synonyms. However, PEGs mainly refer to oligomers and polymers with molecular masses below 20,000 g/mol, while PEOs are polymers with molecular masses above 20,000 g/mol, and POEs are polymers of any molecular mass. Relatively small molecular weight PEGs are produced by the chemical reaction between ethylene oxide and water or ethylene glycol (or other ethylene glycol oligomers), as catalyzed by acidic or basic catalysts. To produce PEO or high-molecular weight PEGs, synthesis is performed by suspension polymerization. It is necessary to hold the growing polymer chain in solution during the course of the poly-condensation process. The reaction is catalyzed by magnesium-, aluminum-, or calciumorganoelement compounds. To prevent coagulation of polymer chains in the solution, chelating additives such as dimethylglyoxime are used Safety Evaluation of Polyethyene Glycol (PEG) Compounds for Cosmetic Use: Toxicol Res 2015; 31:105-136 The Korean Society of Toxicology

http://doi.org/10.5487/TR.2015.31.2.105

for nonviphenol:

Nonylphenol was studied for oral toxicity in rats in a 28-day repeat dose toxicity test at doses of 0, 4, 15, 60 and 250 mg/kg/day. Changes suggesting renal dysfunction were mainly noted in both sexes given 250 mg/kg. Liver weights were increased in males given 60 mg/kg and in both sexes given 250 mg/kg group. Histopathologically, hypertrophy of the centrilobular hepatocytes was noted in both sexes given 250 mg/kg. Kidney weights were increased in males given 250 mg/kg and macroscopically, disseminated white spots, enlargement and pelvic dilatation were noted in females given 250 mg/kg. Histopathologically, the following lesions were noted in the 250 mg/kg group: basophilic change of the proximal tubules in both sexes, single cell necrosis of the proximal tubules, inflammatory cell infiltration in the interstitium and casts in females, basophilic change and dilatation of the collecting tubules in both sexes given 250 mg/kg. In the caecum, macroscopic dilatation was noted in both sexes given 250 mg/kg. Almost all changes except those in the kidney disappeared after a 14-day recovery period. The NOELs for males and females are considered to be 15 mg/kg/day and 60 mg/kg/day, respectively, under the conditions of the present study. Nonylphenol was not mutagenic to Salmonella typhimurium, TA100, TA1535, TA98, TA1537 and Escherichia coli WP2 uvrA, with or without an excogeneous metabolic activation system.

Nonylphenol induced neither structural chromosomal aberrations nor polyploidy in CHL/IU cells, in the absence or presence of an exogenous metabolic activation system.

Alkyl ether sulfates (alcohol or alkyl ethoxysulfates) (AES) (syn: AAASD ,alkyl alcohol alkoxylate sulfates, SLES) are generally classified according to Comité Européen des Agents de Surface et leurs Intermédiaires Organiques (CESIO) as Irritant (Xi) with the risk phrases R38 (Irritating to skin) and R36 (Irritating to eyes). An exception has been made for AES (2-3E0) in a concentration of 70-75% where R36 is substituted with R41 (Risk of serious damage to eyes).

AES are not included in Annex 1 of the list of dangerous substances of Council Directive 67/548/EEC.

In assessing this family the Cosmetic Ingredient Review (CIR) Expert Panel recognized that most of the acute oral toxicity, dermal irritation and sensitization, subchronic and chronic oral toxicity, reproductive and developmental toxicity, carcinogenicity, and photosensitization studies have been conducted on ammonium laureth sulfate and sodium laureth sulfate. Sodium and ammonium laureth sulfate have not evoked adverse responses in any toxicological testing, including acute oral toxicity, sub-chronic and chronic oral toxicity, reproductive and develop-mental toxicity, carcinogenicity, and photosensitization studies. These data, however, are considered a sufficient basis for concluding that the other ingredients are safe in the practices of use and concentration described in the safety assessment because of the fundamental chemical similarities between them and because they all are chemically similar salts(salts are expected to be dissociated in any product formulation independent of whether the salt is sodium, ammonium, magnesium, or zinc) of sulfated ethoxylated alcohols, and they all function as surfactants in cosmetic formulations. Based on these considerations, safety test data on one ingredient may be extrapolated to all of them. The panel noted that sodium laureth sulfate and ammonium laureth sulfate can produce eye and/or skin irritation in experimental animals and in some human test subjects; irritation may occur in some users of cosmetic formulations containing these ingredients. The irritant effects however, are similar to those produced by other detergents, and the severity of the irritation appears to increase directly with concentration Acute toxicity: AES are of low acute toxicity. Neat AES are irritant to skin and eyes. The irritation potential of AES containing solutions depends on concentration. Local dermal effects due to direct or indirect skin contact with AES containing solutions in hand-washed laundry or hand dishwashing are not of concern because AES is not a contact sensitiser and AES is not expected to be irritating to the skin at in-use concentrations. The available repeated dose toxicity data demonstrate the low toxicity of AES. Also, they are not considered to be mutagenic, genotoxic or carcinogenic, and are not reproductive or developmental toxicants. The consumer aggregate exposure from direct and indirect skin contact as well as from the oral route via dishware residues results in an estimated total body burden of 29 ug /kg bw/day. AES are easily absorbed in the intestine in rats and humans after oral administration. Radiolabelled C11 AE3S and C12 AE3S were extensively metabolized in rats and most of the 14C-activity was eliminated via the urine and expired air independently of the route of administration (oral, intraperitoneal or intravenous). The main urinary metabolite from C11 AE3S is propionic acid-3-(3EO)-sulfate. For C12 and C16 AE3S, the main metabolite is acetic acid-2-(3EO)-sulfate. The alkyl chain appears to be oxidised to CO2 which is expired. The EO-chain seems to be resistant to metabolism.

AES are better tolerated on the skin than, e.g., alkyl sulfates and it is generally agreed that the irritancy of AES is lower than that of other anionic surfactants. Alkyl chain lengths of 12 carbon atoms are considered to be more irritating to the skin compared to other chain lengths. The skin irritating properties of AES normally decrease with increasing level of ethoxylation. Undiluted AES should in general be considered strongly irritating. Even at concentrations of 10% moderate to strong effects can be expected. However, only mild to slight irritation was observed when a non-specified AES was applied at 1% to the skin.

Subchronic toxicity: A 90-day subchronic feeding study in rats with 1% of AE3S or AE6S with alkyl chain lengths of C12-14 showed only an increased liver/body weight ratio. In a chronic oral study with a duration of 2 years, doses of C12-AE3S of 0.005 - 0.05% in the diet or drinking water had no effects on rats. The concentration of 0.5% sometimes resulted in increased kidney or liver weight.

Subchronic 21-day repeat dose dietary studies showed low toxicity of compounds with carbon lengths of C12-15, C12-14 and C13-15 with sodium or ammonium alkyl ethoxylates with POE (polyoxyethylene) n=3. One study indicated that C16-18 POE n=18 had comparable low toxicity. No-observed-adverse-effect levels (NOAELs) range from 120 to 468 mg/kg/day, similar to a NOAEL from a 90-day rat gavage study with NaC12-14 POE n=2(CAS RN 68891-38-3), which was reported to be 225 mg/kg/day. In addition, another 90-day repeat dose dietary study with NaC12-15 POE n=3 (CAS RN 68424-50-0) resulted in low toxicity, with a NOAEL of greater than approximately 50 mg/kg/day (calculated based on dose of 1000 ppm in diet). Effects were usually related to hepatic hypertrophy, increased liver weight, and related increases in haematological endpoints related to liver enzyme induction.

Reproductive and developmental toxicity: No evidence of reproductive and teratogenic effects was seen in a two-generation study in rats fed with a mixture (55:45) of AES and linear alkylbenzene sulfonates. Dietary levels of 0.1, 0.5, and 1% were administered to the rats either continuously or during the period of major organogenesis during six pregnancies. No changes in reproductive or embryogenic parameters were observed.

Based on this study an overall no-observed-adverse-effect level (NOAEL) for systemic effects was 0.1%, which was 86.6 mg/kg/day for the F0 generation, and 149.5 mg/kg/day for the F1 generation. The NOAEL of 86.6 mg/kg/day was selected as the toxicology endpoint for the chronic risk assessment for the sulfate derivatives.

Carcinogenicity: Chronic dietary studies conducted with rats showed no incidence of cancer and no effects at the concentrations tested (lowest dose tested was ca 75 mg/kg/day).

NOTE: Some products containing AES/ SLES have been found to also contain traces (up to 279 ppm) of 1,4-dioxane; this is formed as a by-product during the ethoxylation step of its synthesis. The U.S. Food and Drug Administration recommends that these levels be monitored. The U.S. Environmental Protection Agency classifies 1,4-dioxane to be a probable human carcinogen (not observed in epidemiological studies of workers using the compound, but resulting in more cancer cases in controlled animal studies), and a known irritant with a no-observed-adverse-effects level of 400 milligrams per cubic meter at concentrations significantly higher than those found in commercial products. Under Proposition 65, 1,4-dioxane is classified in the U.S. state of California to cause cancer. The FDA encourages manufacturers to remove 1,4-dioxane, though it is not required by federal law.

Sensitising potential: Polyethers, for example, ethoxylated surfactants and polyethylene glycols, are highly susceptible towards air oxidation as the ether oxygens will stabilize intermediary radicals involved. Investigations of a chemically well-defined alcohol (pentaethylene glycol mono-n-dodecyl ether) ethoxylate, showed that polyethers form complex mixtures of oxidation products when exposed to air. Sensitization studies in guinea pigs revealed that the pure nonoxidized surfactant itself is nonsensitizing but that many of the investigated oxidation products are sensitizers. Two hydroperoxides were identified in the oxidation mixture, but only one (16-hydroperoxy-3,6,9,12,15-pentaoxaheptacosan-1-ol) was stable enough to be isolated. It was found to be a strong sensitizer in LLNA (local lymph node assay for detection of sensitization capacity). The formation of other hydroperoxides was indicated by the detection of their corresponding aldehydes in the oxidation mixture .

On the basis of the lower irritancy, nonionic surfactants are often preferred to ionic surfactants in topical products. However, their susceptibility towards autoxidation also increases the irritation. Because of their irritating effect, it is difficult to diagnose ACD to these compounds by patch testing **Toxicokinetics:**

| | Following oral exposure. AFS is readily absorbed in the destrointestinal tract in human and rat and excreted principally via the urine or foegee |
|---|--|
| | Following oral exposure, AES is readily absorbed in the gastrointestinal tract in human and rat and excreted principally via the urine or faeces depending on the length of the ethoxylate chain but independently of the route of administration. Once absorbed, AES is extensively metabolized by beta- or omega oxidation. The alkyl chain appears to be oxidized to CO2 which is expired. The EO-chain seems to be resistant to metabolism. Regarding the different anions, it is expected that the salts will be converted to the acid form in the stomach. This means that for all types of parent chemical the same compound structure eventually enters the small intestine. Hence, the situation will be similar for compounds originating from different salts and therefore no differences in uptake are anticipated. The length of the ethoxylate portion in an AES molecule seems to have an important impact on the biokinetics of AES in humans and in the rat. Alcohol ethoxysulfates with longer ethoxylate chains (>7-9 EO units) are excreted at a higher proportion in the faeces. This is however not of interest for the AES within this category as their ethoxylation grade is 1 to 2.5. Dermal absorption There are two reliable and relevant studies available assessing the dermal absorption rate of AES. The study with AES (C12 -14; 2 EO) Na (CAS 68891-38-3) was performed according to OECD guideline 428 with human skin of the abdomen region (3 donors, n=2). The test substance was applied at a concentration of 10% for 24 h The mean amount removed from the skin surface (skin wash) ranged from 87.16% to 94.56% of the dose applied. The amounts in the receptor could not be quantified, since it was below the analytical limit of quantification (LOQ). The mean recovery in the two first tape strips was 1.48% during all performed experiments. In the further 18 tape strips a mean recovery of 2.86% was documented. The recovery values for the cryocuts have accounted 0.56% in mean. |
| | The mean absorbed dose, sum of the amounts found in urine, faeces and skin in the experiment with washing was about 0.1% and 0.9% |
| | The mean recovery values varied from 98.6% to 103%. |
| | Taking the results of both studies together the dermal absorption is very low. The in vitro study with human skin indicated the dermal absorption to be 0.56% within 24 h and the in vivo study indicated the dermal absorption to be 0.9% within 48 h. The mean recovery rates on the skin are greater than 87%. These data demonstrate that the test substance remains on the skin surface. Thus, the value of 0.9% dermal absorption is taken for the dermal absorption. |
| | Reterences: Danish EPA - Environmental and Health Assessment of Substances in Household Detergents and Cosmetic Detergent Products (2001). |
| | Environmental Project No. 615, pp. 24-28 HERA (2003). Human & Environmental Risk Assessment on ingredients of European household cleaning products Alcohol Ethoxysulphates, |
| | Human Health Risk Assessment Draft, 2003. http://www.heraproject.com. Final Report of the Amended Safety Assessment of Sodium Laureth Sulfate and Related Salts of Sulfated Ethoxylated Alcohols: (nternational |
| | Journal of Toxicology 29 (Supplement 3) 151S-161S: 2010 |
| | |
| | The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis. |
| 2-METHYL- 4-ISOTHIAZOLIN-3-ONE | Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of appropriate studies with similar materials using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies. |
| | cellular DNA. |
| | The predominant fate of the thiazole ring is oxidative ring scission catalysed by cytochrome P450 (CYP) and formation of the corresponding |
| | alpha-dicarbonyl metabolites and thioamide derivatives. The well-established toxicity associated with thioamides and thioureas has led to the speculation that thiazole toxicity is attributed to ring scission yielding the corresponding thioamide metabolite. Ring opening has also been observed in benzothiazoles. For instance, benzothiazole itself is converted to S-methylmercaptoaniline. Acute toxicity data show that 1,2-benzisothiazoline-3-one (BIT) is moderately toxic by the oral and dermal routes but that this chemical is a |
| | severe eye irritant. Irritation to the skin from acute data show only mild skin irritation , but repeated dermal application indicated a more significant skin irritation response. |
| | The neurotoxicity observed in the rat acute oral toxicity study (piloerection and upward curvature of the spine at 300 mg/kg and above; decreased activity, prostration, decreased abdominal muscle tone, reduced righting reflex, and decreased rate and depth of breathing at 900 mg/kg) and the acute dermal toxicity study (upward curvature of the spine was observed in increased incidence, but this was absent after day 5 post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg) were felt to be at exposures in excess of those expected from the use pattern of this post-dose at a dose of 2000 mg/kg). |
| 1,2-BENZISOTHIAZOLINE-3-ONE | such effects would not be observed at estimated exposure doses. |
| | incidence of forestomach hyperplasia, and non-glandular stomach lesions in rats. In dogs, the effects occurred at lower doses than in rats, and included alterations in blood chemistry (decreased plasma albumin, total protein, and alanine aminotransferase) and increased absolute liver weight. |
| | Developmental toxicity studies were conducted in rats with maternal effects including decreased body weight gain, decreased food consumption, and clinical toxicity signs (audible breathing, haircoat staining of the anogenital region, dry brown material around the nasal area) as well as increased mortality. Developmental effects consisted of increases in skeletal abnormalities (extra sites of ossification of skull bones, unossified sternebrae) but not external or visceral abnormalities. |
| | Reproductive toxicity: In a two- generation reproduction study, parental toxicity was observed at 500 ppm and was characterized by lesions in the stomach. In pups, toxic effects were reported at 1000 ppm and consisted of preputial separation in males and impaired growth and |
| BARIUM SULFATE & AMMONIA | survival in both sexes. The reproduction study did not show evidence of increased susceptibility of offspring. |
| ANHYDROUS LIQUEFIED & | |
| 2-METHYL- | No significant acute toxicological data identified in literature search. |
| 4-ISOTHIAZOLIN-3-ONE & 1,2-BENZISOTHIAZOLINE-3-ONE | |
| | Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to bind levels of highly irritating compound. Main |
| AMMONIA ANHYDROUS | criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent |
| ISOTHIAZOLINONES, MIXED & | asuma-like symptoms within minutes to hours or a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack |
| 2-METHYL- 4-ISOTHIAZOLIN-3-ONE | of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after |

| | exposure ceases. The disorder is characterized by di | fficulty breathing, cough and mucus p | roduction. |
|---|---|--|--|
| ISOTHIAZOLINONES, MIXED & 2-METHYL- 4-ISOTHIAZOLIN-3-ONE & 1,2-BENZISOTHIAZOLINE-3-ONE | The following information refers to contact allergens a Contact allergies quickly manifest themselves as con eczema involves a cell-mediated (T lymphocytes) imm involve antibody-mediated immune reactions. The sig distribution of the substance and the opportunities for distributed can be a more important allergen than one clinical point of view, substances are noteworthy if the In light of potential adverse effects, and to ensure a h has been established with the objective of ensuring a required that risk assessment of biocidal products is of assessment of the biocidal products are the utilization thus the exposure of humans and the environment to Humans may be exposed to biocidal products in diffe intended for industrial sectors or professional uses or non-professional users. In addition, potential exposur environment, for example through drinking water, the should be paid to the exposure of vulnerable sub-pop domestic animals can be exposed indirectly following of route (inhalation, dermal contact, and ingestion) ar and duration. | as a group and may not be specific to tact eczema, more rarely as urticaria of mune reaction of the delayed type. Ott gnificance of the contact allergen is no r contact with it are equally important a with stronger sensitising potential wit ey produce an allergic test reaction in harmonised risk assessment and mana high level of protection of human and carried out before they can be placed in instructions that defines the dosage, the biocidal substance. Frent ways in both occupational and do nly, whereas other biocidal products (if. food chain, as well as through atmosp pulations, such as the elderly, pregnan the application of biocidal products. F and pathway (food, drinking water, resid | this product. or Quincke's oedema. The pathogenesis of contact her allergic skin reactions, e.g. contact urticaria, t simply determined by its sensitisation potential: the A weakly sensitising substance which is widely th which few individuals come into contact. From a more than 1% of the persons tested. agement, the EU regulatory framework for biocides animal health and the environment. To this aim, it is on the market. A central element in the risk application method and amount of applications and omestic settings. Many biocidal products are re commonly available for private use by a the general public) may occur indirectly via the oheric and residential exposure. Particular attention t women, and children. Also pets and other Furthermore, exposure to biocides may vary in terms lential, occupational) of exposure, level, frequency |
| ISOTHIAZOLINONES, MIXED & 2-METHYL- 4-ISOTHIAZOLIN-3-ONE | domestic animals can be exposed indirectly following the application of biocidal products. Furthermore, exposure to biocides may vary in terms of route (inhalation, dermal contact, and ingestion) and pathway (food, drinking water, residential, occupational) of exposure, level, frequency and duration. The European Union has reclassified several formaldehyde-releasing agents (FRAs) such as methylenedimorpholine (MBM), oxazolidine (MBO) and hydroxyproythemine (HPT) as category 18 accrinogens. Previously, formaldehyde tiself was classed as a carcinogen – but formaldehyde-releasing agents were not. This is no longer the case. Based on this regulation, formulations for which the maximum theoretical concentration of releasable formaldehyde is nor ten as 1000 ppm (>0.1%), have to be labelled as carcinogenic. Water mix metalworking fluids are subject to contamination by bacteria and fungi, and the control of this is an essential part of good fluid maintenance. The use of preservatives both within the formulation and tark-side treatment plays a significant contribution in the protection of potentially have releases that could cause health problems for workers. A large proportion of bactericides on the market today are classed as formaldehyde releasing biocides which means that under specific conditions they release simal anounts of formaldehyde and to re-classify formaldehyde as a category 1 bH350 carcinogen and category 2 mutagen in June 2015. It has also been proposed by the ECHA Risk Assessment Committee (RAC) that formaldehyde release biocides should be classified the same as formaldehyde generators. Formaldehyde is released extention dively used antimicrobials, biocides, microbiocides). Formaldehyde may be generators (releasers) are often used as preservatives (antimicrobials, biocides, microbiocides). Formaldehyde may be generators (releasers) are often used as preservatives (antimicrobials, biocides, microbiocides). Formaldehyde may be generators (re | | |
| Aquita Taxiaitu | | Caroinogonicity | × |
| Skin Irritation/Corrosion | × | Reproductivity | X |
| Serious Eye Damage/Irritation | × | STOT - Single Exposure | × |
| Respiratory or Skin | ٠ | STOT - Repeated Exposure | × |

 Data either not available or does not fill the criteria for classification
 Data available to make classification Legend:

×

х

STOT - Repeated Exposure

Aspiration Hazard

SECTION 12 Ecological information

sensitisation Mutagenicity ~

×

Toxicity

| | Endpoint | Test Duration (hr) | Species | Value | Source |
|-------------------------|------------------|--------------------|---------------|------------------|------------------|
| ARDEX WPM155 Rapid Plus | Not Available | Not Available | Not Available | Not Available | Not Available |

| Endpoint | Test Duration (hr) | Species | · | Value | Source |
|-----------|---|--|--|--|--|
| EC50 | 72h | Algae or other aquatic plants | | >1.15mg/l | 2 |
| EC50 | 48h | Crustacea 32mg/L | | 32mg/L | 2 |
| NOEC(ECx) | 72h | Algae or other aquatic plants | | >=1.15mg/l | 2 |
| LC50 | 96h | Fish | | >3.5mg/l | 2 |
| Endpoint | Test Duration (hr) | Species | | Value | Source |
| BCF | 1008h | Fish <17-53 | | <17-53 | 7 |
| Endpoint | Test Duration (hr) | Species | Va | alue | Source |
| EC50 | 48h | Crustacea | >9< | 2.578mg/L | 4 |
| LC50 | 96h | Fish | 0. | 068mg/l | 2 |
| NOEC(ECx) | 744h | Fish | <(|).048mg/L | 2 |
| Endpoint | Test Duration (hr) | Species | ١ | /alue | Source |
| LC50 | 96h | Fish | (|).129mg/l | 2 |
| EC50 | 72h | Algae or other aquatic plants 0.006mg/L | | 2 | |
| EC50 | 48h | Crustacea | Crustacea 0.007mg/l | | 2 |
| EC50 | 96h | Algae or other aquatic plants | (| 0.036mg/L | 2 |
| NOEC(ECx) | 48h | Algae or other aquatic plants | < | 0.001mg/L | 2 |
| Endpoint | Test Duration (hr) | Species | Value | | Source |
| EC50 | 72h | Algae or other aquatic plants | 0.057mg/L | | 2 |
| EC50 | 48h | Crustacea | 0.189-0.257mg/L | | 4 |
| EC50 | 96h | Algae or other aquatic plants | 0.061mg/L | | 2 |
| LC50 | 96h | Fish | 0.081-0.122mg/L | | 4 |
| NOEC(ECx) | 96h | Algae or other aquatic plants | Algae or other aquatic plants 0.01mg/l | | 2 |
| Endpoint | Test Duration (hr) | Species | Valu | e | Source |
| EC50 | 72h | Algae or other aquatic plants | 0.07 | mg/L | 2 |
| EC50 | 48h | Crustacea | 0.09 | 7mg/L | 4 |
| NOEC(ECx) | 72h | Algae or other aquatic plants | 0.04 | mg/L | 2 |
| | | — | | | |
| | EC50 EC50 NOEC(ECx) LC50 Endpoint BCF Endpoint EC50 LC50 NOEC(ECx) Ec50 NOEC(ECx) | EC50 72h EC50 48h NOEC(ECx) 72h LC50 96h Endpoint Test Duration (hr) BCF 1008h Endpoint Test Duration (hr) EC50 48h LC50 96h EC50 48h LC50 96h NOEC(ECx) 744h Endpoint Test Duration (hr) LC50 96h EC50 72h EC50 96h EC50 72h EC50 96h NOEC(ECx) 48h EC50 96h NOEC(ECx) 48h EC50 96h NOEC(ECx) 48h EC50 72h EC50 96h NOEC(ECx) 96h NOEC(ECx) 96h NOEC(ECx) 96h NOEC(ECx) 96h | EC5072hAlgae or other aquatic plantsEC5048hCrustaceaNOEC(ECx)72hAlgae or other aquatic plantsLC5096hFishEndpointTest Duration (hr)SpeciesBCF1008hFishEC5048hCrustaceaLC5096hFishEC5048hCrustaceaLC5096hFishNOEC(ECx)74hFishEC5048hCrustaceaLC5096hFishNOEC(ECx)74hFishEC5096hFishEC5096hFishEC5072hAlgae or other aquatic plantsEC5072hAlgae or other aquatic plantsEC5096hAlgae or other aquatic plantsEC5096hAlgae or other aquatic plantsLC5096hAlgae or other aquatic plantsEC5096hAlgae or other aquatic plantsEC5096h </td <td>EC50 72h Algae or other aquatic plants 3 EC50 48h Crustacea 3 NOEC(ECx) 72h Algae or other aquatic plants 3 LC50 96h Fish 3 Endpoint Test Duration (hr) Species 7 BCF 1008h Fish 7 Endpoint Test Duration (hr) Species 7 EC50 48h Crustacea 5 LC50 96h Fish 00 NOEC(ECx) 74h Fish 00 LC50 96h Fish 00 EC50 72h Algae or other aquatic plants 00 EC50 72h Algae or other aquatic plants 00 NOEC(ECx) 48h Crustacea 0.189 EC50 72h Algae or other aquatic plants 0.067</td> <td>EC50 72h Algae or other aquatic plants >1.15mg/l EC50 48h Crustacea 32mg/L NCEC(ECx) 72h Algae or other aquatic plants >=1.15mg/l LC50 96h Fish >3.5mg/l Endpoint Test Duration (hr) Species Value BCF 1008h Fish <17-53</td> Endpoint Test Duration (hr) Species Value EC50 48h Crustacea >92.578mg/L LC50 96h Fish 0.068mg/L LC50 96h Fish 0.068mg/L LC50 96h Fish 0.048mg/L NDEC(ECx) 744h Fish 0.129mg/L LC50 96h Fish 0.129mg/L LC50 96h Fish 0.006mg/L LC50 96h Algae or other aquatic plants 0.007mg/L EC50 72h Algae or other aquatic plants 0.036mg/L NDEC(ECx) 48h Crustacea 0.189-0.257mg/L EC50 72h Algae or other aquatic plants 0.057mg/L | EC50 72h Algae or other aquatic plants 3 EC50 48h Crustacea 3 NOEC(ECx) 72h Algae or other aquatic plants 3 LC50 96h Fish 3 Endpoint Test Duration (hr) Species 7 BCF 1008h Fish 7 Endpoint Test Duration (hr) Species 7 EC50 48h Crustacea 5 LC50 96h Fish 00 NOEC(ECx) 74h Fish 00 LC50 96h Fish 00 EC50 72h Algae or other aquatic plants 00 EC50 72h Algae or other aquatic plants 00 NOEC(ECx) 48h Crustacea 0.189 EC50 72h Algae or other aquatic plants 0.067 | EC50 72h Algae or other aquatic plants >1.15mg/l EC50 48h Crustacea 32mg/L NCEC(ECx) 72h Algae or other aquatic plants >=1.15mg/l LC50 96h Fish >3.5mg/l Endpoint Test Duration (hr) Species Value BCF 1008h Fish <17-53 |

DO NOT discharge into sewer or waterways.

Persistence and degradability

| Ingredient | Persistence: Water/Soil | Persistence: Air |
|-------------------------------|-------------------------|------------------|
| ammonia anhydrous liquefied | LOW | LOW |
| 2-methyl-4-isothiazolin-3-one | HIGH | HIGH |

Bioaccumulative potential

| Ingredient | Bioaccumulation |
|---|------------------------|
| nonylphenol sulfate, ethoxylated, sodium salt | LOW (BCF = 150) |
| ammonia anhydrous liquefied | LOW (LogKOW = 0.229) |
| 2-methyl-4-isothiazolin-3-one | LOW (LogKOW = -0.8767) |

Mobility in soil

| Ingredient | Mobility |
|-------------------------------|-------------------|
| ammonia anhydrous liquefied | LOW (KOC = 14.3) |
| 2-methyl-4-isothiazolin-3-one | LOW (KOC = 27.88) |

SECTION 13 Disposal considerations

| Waste treatment methods | | |
|------------------------------|---|--|
| Product / Packaging disposal | DO NOT allow wash water from cleaning or process equipment to enter drains. It may be necessary to collect all wash water for treatment before disposal. In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. Where in doubt contact the responsible authority. | |

| Recycle wherever possible. Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified. Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or incineration in a licensed apparatus (after admixture with suitable combustible material). Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed. |
|--|
| |

SECTION 14 Transport information

| Labels Required | |
|------------------|----------------|
| Marine Pollutant | NO |
| HAZCHEM | Not Applicable |

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

| Product name | Group |
|---|---------------|
| barium sulfate | Not Available |
| nonylphenol sulfate, ethoxylated, sodium salt | Not Available |
| ammonia anhydrous liquefied | Not Available |
| isothiazolinones, mixed | Not Available |
| 2-methyl-4-isothiazolin-3-one | Not Available |
| 1,2-benzisothiazoline-3-one | Not Available |

14.7.3. Transport in bulk in accordance with the IGC Code

| Product name | Ship Type |
|---|---------------|
| barium sulfate | Not Available |
| nonylphenol sulfate, ethoxylated, sodium salt | Not Available |
| ammonia anhydrous liquefied | Not Available |
| isothiazolinones, mixed | Not Available |
| 2-methyl-4-isothiazolin-3-one | Not Available |
| 1,2-benzisothiazoline-3-one | Not Available |

SECTION 15 Regulatory information

| Safety, health and environmental regulations / legislation specific for the substance or mixture | | |
|--|---|--|
| barium sulfate is found on the fol | llowing regulatory lists | |
| Australian Inventory of Industrial Ch | nemicals (AIIC) | International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS) |
| nonylphenol sulfate, ethoxylated, sodium salt is found on the following regulatory lists | | |
| Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals | | Australian Inventory of Industrial Chemicals (AIIC) |
| ammonia anhydrous liquefied is | found on the following regulatory lists | |
| Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5 | | Australian Inventory of Industrial Chemicals (AIIC) |
| isothiazolinones, mixed is found | on the following regulatory lists | |
| Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals | | |
| 2-methyl-4-isothiazolin-3-one is found on the following regulatory lists | | |
| Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6 | | Australian Inventory of Industrial Chemicals (AIIC) |
| 1,2-benzisothiazoline-3-one is for | und on the following regulatory lists | |
| Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals | | Australian Inventory of Industrial Chemicals (AIIC) |
| National Inventory Status | | |
| National Inventory | Status | |
| Australia - AIIC / Australia Non-Industrial Use | No (isothiazolinones, mixed) | |

| National Inventory | Status |
|-------------------------------|---|
| Canada - DSL | Yes |
| Canada - NDSL | No (barium sulfate; nonylphenol sulfate, ethoxylated, sodium salt; ammonia anhydrous liquefied; isothiazolinones, mixed; 2-methyl-4-isothiazolin- 3-one; 1,2-benzisothiazoline-3-one) |
| China - IECSC | Yes |
| Europe - EINEC / ELINCS / NLP | No (isothiazolinones, mixed) |
| Japan - ENCS | No (isothiazolinones, mixed) |
| Korea - KECI | Yes |
| New Zealand - NZIoC | Yes |
| Philippines - PICCS | Yes |
| USA - TSCA | No (isothiazolinones, mixed) |
| Taiwan - TCSI | Yes |
| Mexico - INSQ | No (isothiazolinones, mixed) |
| Vietnam - NCI | Yes |
| Russia - FBEPH | Yes |
| Legend: | Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration. |

SECTION 16 Other information

| Revision Date | 07/09/2023 |
|---------------|------------|
| Initial Date | 07/09/2023 |

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC - TWA: Permissible Concentration-Time Weighted Average PC - STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit. IDLH: Immediately Dangerous to Life or Health Concentrations ES: Exposure Standard OSF: Odour Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value **BCF: BioConcentration Factors** BEI: Biological Exposure Index AIIC: Australian Inventory of Industrial Chemicals DSL: Domestic Substances List NDSL: Non-Domestic Substances List IECSC: Inventory of Existing Chemical Substance in China EINECS: European INventory of Existing Commercial chemical Substances ELINCS: European List of Notified Chemical Substances NLP: No-Longer Polymers ENCS: Existing and New Chemical Substances Inventory KECI: Korea Existing Chemicals Inventory NZIoC: New Zealand Inventory of Chemicals PICCS: Philippine Inventory of Chemicals and Chemical Substances TSCA: Toxic Substances Control Act TCSI: Taiwan Chemical Substance Inventory INSQ: Inventario Nacional de Sustancias Químicas NCI: National Chemical Inventory FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.